Takeda Pharmaceuticals U.S.A. Inc.
1 Takeda Pkwy
About Takeda Pharmaceutical
Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.
In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.
The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.
In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.
At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.
We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.
Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.
The people and culture at Takeda and Millennium make all the difference.
Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.
As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.
June 12, 1781
Founder: Chobei Takeda
CEO: Christophe Weber
CMO (Medical) and CSO (Scientific): Andrew Plump
CFO: James Kehoe
Please click here for Takeda job opportunities.
Tweets by Takeda
873 articles with Takeda Pharmaceutical
New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
Data to be discussed with global health authorities, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
The Chinese biopharma market is booming as more and more companies eye breaking into that rich market. Christophe Weber, chief executive officer of pharma giant Takeda, views its China programs as its second-biggest business behind the United States.
leon-nanodrugs Supports Takeda in a Feasibility Assessment of leon’s Proprietary MicroJet Reactor (MJR®) Nano-Technology
leon-nanodrugs GmbH's proprietary MicroJet Reactor nano-technology has been selected by Takeda Pharmaceutical Company Ltd. for a feasibility assessment that could potentially lead to the development of an innovative formulation of one of their current pipeline products.
Seattle-based Presage Biosciences made several key moves today that include a $6 million investment from pharma giants Takeda and Celgene and also tapped a new chief executive officer.
Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint.
Takeda Receives Clearance from the United States Federal Trade Commission for the Proposed Acquisition of Shire plc
Takeda Pharmaceutical Company Limited announces that it has received unconditional clearance from the United States Federal Trade Commission (“FTC”) for the proposed acquisition of Shire plc announced on May 8, 2018 (the “Acquisition”).
Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix
The number of Securities tendered into the Bid, together with all Securities owned by Takeda and its affiliates, represents or gives access to 96.03% of the voting rights represented or given access to by all of the outstanding Securities on a fully diluted basis.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
Takeda holds the grand opening of Takeda Global Headquarters in Nihonbashi, Tokyo, Japan.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.
A group of Takeda Pharmaceutical shareholders’ bid to halt the acquisition of Dublin-based Shire failed to gain traction.
The biopharma industry generally views vaccines to be low-margin investments. From a public health perspective, however, vaccines can be one of the best investment dollars.
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
A consumer advocacy group, Public Citizen, has petitioned the FDA to pull the drug, Uloric, off the market.
Days after President Donald Trump signed the Right-to-Try legislation there are still many uncertainties about the law.
Cell Medica today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease is somewhat low.